CliffBio
small molecule

CITALOPRAM HYDROBROMIDE

CITALOPRAM HYDROBROMIDE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameCITALOPRAM HYDROBROMIDE
Active ingredientCITALOPRAM HYDROBROMIDE
StrengthEQ 20MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2006
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.